SCHEMBL5760004

SCHEMBL5760004

COC(OC)C(=O)OCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.60
TDP1 Q9NUW8 3/20 0.53
MAPK1 P28482 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
KMT2A Q03164 2/20 0.53
SLC6A2 P23975 1/20 0.53
SLC6A3 Q01959 1/20 0.53
LMNA P02545 3/20 0.49
HCAR2 Q8TDS4 1/20 0.49
NPC1 O15118 2/20 0.46
MAPT P10636 2/20 0.46
RAB9A P51151 1/20 0.46
HPGD P15428 1/20 0.46
ELANE P08246 1/20 0.46
CYP3A4 P08684 1/20 0.45
TSHR P16473 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MEN1 O00255 1/20 0.44
ATM Q13315 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11402422 0.91 ALDH1A1 (0.55) ALDH1A1TDP1MAPK1L3MBTL1KMT2A
SCHEMBL20091143 0.83 ALDH1A1 (0.58) ALDH1A1TDP1MAPK1L3MBTL1KMT2A
SCHEMBL20435071 0.83 ALDH1A1 (0.58) ALDH1A1TDP1MAPK1L3MBTL1KMT2A
SCHEMBL8549949 0.82 ALDH1A1 (0.57) ALDH1A1TDP1MAPK1L3MBTL1KMT2A
SCHEMBL11906741 0.82 ALDH1A1 (0.58) ALDH1A1TDP1MAPK1L3MBTL1KMT2A
SCHEMBL7161008 0.81 HCAR2 (0.51) ALDH1A1TDP1MAPK1L3MBTL1LMNA
SCHEMBL11908509 0.81 ALDH1A1 (0.56) ALDH1A1TDP1MAPK1L3MBTL1KMT2A
SCHEMBL7667014 0.81 ALDH1A1 (0.54) ALDH1A1TDP1MAPK1L3MBTL1KMT2A
SCHEMBL22485617 0.81 ALDH1A1 (0.51) ALDH1A1TDP1MAPK1L3MBTL1KMT2A
SCHEMBL23135770 0.80 ALDH1A1 (0.55) ALDH1A1TDP1MAPK1L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1392295-B1 CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES HOFFMANN LA ROCHE (CH) 2006-05-31 EP disclosed
EP-1392295-A1 CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES F. Hoffmann-La Roche AG (CH) 2004-03-03 EP disclosed
US-6642389-B2 For therapy of diabetes HOFFMANN-LA ROCHE INC. 2003-11-04 US disclosed
US-20030055265-A1 Oxazole derivatives HOFFMANN-LA ROCHE INC. 2003-03-20 US disclosed
WO-2002092084-A1 CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055265-A1 Oxazole derivatives PPARD, PPARA, PPARG ALDH1A1 827/4885TDP1 3626/4885MAPK1 1795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.